Welcome to our dedicated page for Abvc Biopharma SEC filings (Ticker: ABVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ABVC BioPharma, Inc. (NASDAQ: ABVC) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including annual and quarterly reports and current reports on Form 8-K. As a clinical-stage biopharmaceutical company focused on oncology/hematology, central nervous system disorders, and ophthalmology, ABVC uses these filings to describe its pipeline, licensing arrangements, financing activities, and other material events.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review management’s discussion of operating results, R&D spending, and the status of key programs such as CNS candidates for major depressive disorder and ADHD, oncology assets with US FDA-approved INDs, and the Vitargus® vitreous substitute device. These reports also outline intellectual property holdings, including patents on Polygala extract-based therapies and ophthalmology technologies, and discuss collaboration structures with partners like AiBtl BioPharma Inc., ForSeeCon Eye Corporation, and OncoX BioPharma Inc.
Current reports on Form 8-K capture specific events, such as licensing agreements, financing transactions, changes in the independent registered public accounting firm, and updates on Nasdaq listing compliance. They also reference press releases announcing financial results for particular quarters, providing timely insight into revenue from services and licensing payments, as well as changes in stockholders’ equity and debt arrangements.
On Stock Titan, ABVC filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items related to clinical progress, licensing economics, or capital structure. Real-time updates from the SEC’s EDGAR system ensure that new 10-K, 10-Q, and 8-K filings, along with any other relevant forms, appear promptly. Users can also monitor disclosures that may relate to executive or director equity awards and other equity incentive matters as described in ABVC’s filings.
ABVC BioPharma, Inc. reported results from its 2026 annual shareholder meeting held on March 26, 2026. A quorum was present, with 10,612,493 common shares representing 41.74% of the voting power entitled to vote.
Shareholders re-elected all director nominees, each receiving over ten million votes in favor. They also approved the reappointment of Simon & Edward, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 10,597,352 votes for, 12,291 against, and 2,850 abstentions.
In addition, shareholders approved the Plan Proposal, with 9,964,400 votes for, 643,419 against, and 4,674 abstentions, indicating broad support among those present for the company’s equity or incentive plan changes.
ABVC BioPharma, Inc. is asking shareholders to vote at its 2026 annual meeting, which will be held virtually via Zoom on March 26, 2026 at 10:00 a.m. EST. Shareholders of record as of January 26, 2026, when 25,423,654 common shares were outstanding, are entitled to one vote per share.
Key items include re‑electing 11 directors, ratifying Simon & Edward, LLP as independent auditor for 2026, and approving an amendment to the 2016 Equity Incentive Plan. The plan amendment would reset the share reserve so that, immediately after the change, it equals 15% of issued and outstanding common stock as of the meeting date, with a continuing 5% annual “evergreen” increase starting in 2027.
Shareholders must vote by proxy in advance; there will be no live voting during the virtual meeting, and signed proxies without specific instructions will be voted “FOR” all nominees and proposals, as recommended unanimously by the Board.
ABVC BioPharma files its annual report describing an early-stage biotech business focused on botanical drugs for CNS and oncology/hematology, plus one ophthalmic medical device. Revenue currently comes mainly from out-licensing intellectual property and CDMO manufacturing services.
The company reports seven drug candidates and one device in various Phase I/II programs for major depressive disorder, ADHD, cancer-related depression, myelodysplastic syndromes, pancreatic cancer and retinal detachment. It holds a broad patent estate across the U.S., Europe and Asia and operates a GMP facility through subsidiary BioKey.
ABVC highlights prior Nasdaq notifications for minimum bid price and stockholders’ equity deficiencies and notes that it subsequently regained compliance with Listing Rule 5550, avoiding a reverse split. The report cites an aggregate market value of non-affiliate common stock of $37 million as of June 30, 2025 and 25,440,407 common shares outstanding as of March 3, 2026. Extensive risk factors emphasize funding needs, lack of approved products, clinical and regulatory uncertainty, concentration of licensing relationships, and potential volatility of the stock.
ABVC BioPharma, Inc. is restating its unaudited quarterly results for the period ended September 30, 2025 after management concluded prior statements should no longer be relied upon. The company reversed $795,950 of previously recognized licensing revenue tied to payments from OncoX and ForSeeCon that were determined to be effectively funded by related party BioFirst or did not meet contractual funding conditions.
ABVC also changed how it valued land acquired from a director in Taiwan, increasing the recorded cost of the property by $798,486 to $4,656,461 based on the fair value of equity and warrants issued. For the nine months ended September 30, 2025, restated results show no revenue, a net loss of $5,360,496, and net cash used in operating activities of $2,398,717. The company reports a working capital deficit of $3,230,901 and states that these conditions raise substantial doubt about its ability to continue as a going concern, noting it will need improved operations, additional capital, or related-party support.
ABVC BioPharma, Inc. reported that its previously issued financial statements for the quarter ended September 30, 2025 should no longer be relied upon because of errors in revenue recognition and fair value measurement. The company reversed an aggregate $795,950 of licensing revenue from OncoX and ForSeeCon after determining much of the cash effectively came from related party BioFirst or did not meet contractual payment conditions, and reclassified those amounts to balances with BioFirst and OncoX.
ABVC also remeasured land acquired from director Shuling Jiang, concluding that the fair value of the equity and warrants issued provides a clearer measure than the prior appraisal-based value. This increased the recorded land cost by $798,486 to $4,656,461. The company identified a material weakness in internal control over financial reporting and plans to amend the affected Form 10-Q. Separately, ABVC’s 2025 Form 10-K shows total assets rising 179% to $21.06 million, driven mainly by strategic land and development-oriented assets in Asia.
ABVC BioPharma, Inc. is asking shareholders to approve three items at its 2026 virtual annual meeting on March 9, 2026. Shareholders will vote on re-electing 11 directors, ratifying Simon & Edward, LLP as auditor for 2026, and increasing shares under the 2016 Equity Incentive Plan.
The equity plan amendment would raise the plan reserve to an amount equal to 15% of the company’s 25,423,654 shares of common stock outstanding as of January 26, 2026, which is estimated at 3,813,548 shares, with a continuing 5% annual “evergreen” increase beginning in 2027.
ABVC BioPharma reports additional unregistered equity sales following a prior offshore offering. Between April 11 and May 27, 2025, the company sold 1,987,557 common shares to 43 Non-U.S. Persons under Regulation S, raising aggregate gross proceeds of about $1,289,750.
Between May 26, 2025, and January 6, 2026, ABVC accepted further subscriptions totaling $2,275,468 on the same terms, issuing 1,500,250 additional common shares at prices between $1.00 and $1.95 per share. These new shares equal about 5.92% of the company’s outstanding common stock as of this filing. Investors entered stock purchase agreements and Voting Rights Proxy Agreements transferring their voting rights to chairman Eugene Jiang. The securities were sold privately to accredited, Non-U.S. investors, are unregistered, and are subject to resale restrictions under U.S. securities laws.
ABVC BioPharma filed Prospectus Supplement No. 4 to its July 12, 2024 prospectus, registering 1,000,000 shares of common stock underlying a common stock purchase warrant. The supplement also attaches the company’s Q3 2025 Form 10‑Q. Shares outstanding were 24,301,089 as of October 30, 2025; this is a baseline figure, not the amount being offered.
For the nine months ended September 30, 2025, ABVC reported revenue of $795,950 and a net loss of $4,564,546. The company disclosed a working capital deficit of $2,434,951 and noted substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were $192,068 with restricted cash of $661,843. Total assets rose to $21.18 million, reflecting land acquisitions and other noncurrent items.
ABVC BioPharma filed Prospectus Supplement No. 5 updating its April 5, 2024 prospectus covering 11,714,683 shares of common stock. The supplement appends the company’s Form 10-Q for the quarter ended September 30, 2025.
For Q3 2025, revenue was $795,950 and loss from operations was $1,168,410, leading to a net loss attributable to ABVC of $1,246,513. For the nine months, net loss attributable to ABVC was $4,345,610. Cash and cash equivalents were $192,068 with restricted cash of $661,843 as of September 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern, citing a working capital deficit of $2,434,951 and net cash outflows from operating activities of $1,567,264 for the nine months. Shares outstanding were 24,301,089 as of October 30, 2025; this is a baseline figure, not the amount being offered.
ABVC BioPharma filed Prospectus Supplement No. 5 covering 225,500 shares of common stock and updating its May 22, 2024 prospectus with the company’s Form 10‑Q for the quarter ended September 30, 2025.
For Q3 2025, revenue was $795,950 and net loss attributed to ABVC and subsidiaries was $1,246,513. For the nine months ended September 30, 2025, net loss was $4,564,546. Cash and cash equivalents were $192,068 and restricted cash was $661,843. The filing notes a working capital deficit of $2,434,951 and states there is substantial doubt about the company’s ability to continue as a going concern.
Shares outstanding were 24,301,089 as of October 30, 2025. The company also disclosed restatements affecting 2023 and certain 2024 interim figures, primarily related to stock‑based compensation, convertible note accounting, and noncontrolling interests.